UMass Chan Receives $2.2 Million to Fund Gene Therapy for Cockayne Syndrome

UMass Chan Medical School has received $2.2 million from a nonprofit patient-advocacy organization to contract with Andelyn Biosciences to manufacture clinical grade AAV9-CSA vector to treat Cockayne syndrome.

Please click here to be taken to the external linkDownload

News & Press Releases

Press Release

September 18, 2026

Andelyn Biosciences and its Curator® Platform Achieve First FDA-Approved Commercial Gene Therapy Manufacturing Milestone Following the FDA’s Approval of Ultragenyx’s Fayuvi™ for the Treatment of Sanfilippo Syndrome Type A (MPS IIIA)Andelyn Biosciences and its Curator® Platform Achieve First FDA-Approved Commercial Gene Therapy Manufacturing Milestone Following the FDA’s Approval of Ultragenyx’s Fayuvi™ for the Treatment of Sanfilippo Syndrome Type A (MPS IIIA)
Press Release

September 1, 2026

Andelyn Biosciences to Scale Manufacturing for Genprex’s Diabetes Gene Therapy ProgramAndelyn Biosciences to Scale Manufacturing for Genprex’s Diabetes Gene Therapy Program
News

August 22, 2026

The Columbus Dispatch | Fore One Purpose returns to help family battling rare diseaseThe Columbus Dispatch | Fore One Purpose returns to help family battling rare disease
News

August 19, 2026

Bioprocess Insider | Andelyn partners with Queen’s University on gene therapy for GM2 gangliosidosesBioprocess Insider | Andelyn partners with Queen’s University on gene therapy for GM2 gangliosidoses
View All News & Press Releases
By clicking “Accept”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our Privacy Policy for more information.
PreferencesDenyAccept